Nautilus Biotechnology vs Insilico Medicine

Side-by-side comparison of AI visibility scores, market position, and capabilities

Insilico Medicine leads in AI visibility (43 vs 37)
Nautilus Biotechnology logo

Nautilus Biotechnology

EmergingBiotechnology

Single-Molecule Proteomics

Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
32
Perplexity
42
Gemini
35

About

Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.

Full profile
Insilico Medicine logo

Insilico Medicine

ChallengerLife Sciences & BioTech

Drug Discovery & Development

Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1 of 1
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
39
Perplexity
46
Gemini
38

About

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.

Full profile

AI Visibility Head-to-Head

37
Overall Score
43
#1
Category Rank
#1
64
AI Consensus
66
up
Trend
up
32
ChatGPT
39
42
Perplexity
46
35
Gemini
38
31
Claude
48
44
Grok
35

Key Details

Category
Single-Molecule Proteomics
Drug Discovery & Development
Tier
Emerging
Challenger
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Nautilus Biotechnology
Single-Molecule Proteomics
Only Insilico Medicine
Drug Discovery & Development
Insilico Medicine is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.